Top

EJNMMI Research

Published in:

Open Access 01-12-2020 | Metastasis | Short communication

The feasibility of [¹⁸F]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study

Authors: Maren Laasik, Johanna Hynninen, Sarita Forsback, Tommi Noponen, Marko Seppänen, Sakari Hietanen

Published in: EJNMMI Research | Issue 1/2020

Abstract

Rationale

Evaluation of the feasibility of [¹⁸F]EF5-PET/CT scan in identifying hypoxic lesions in ovarian tumors in prospective clinical setting.

Methods

Fifteen patients with a suspected malignant ovarian tumor were scanned with [¹⁸F]EF5 and [¹⁸F]FDG-PET/CT preoperatively. The distribution of [¹⁸F]EF5-uptake, total intraabdominal metabolic tumor volume (TMTV), and hypoxic subvolume (HSV) were assessed.

Results

[¹⁸F]EF5-PET/CT suggested hypoxia in 47% (7/15) patients. The median HSV was 87 cm³ (31% of TMTV). The [¹⁸F]EF5-uptake was detected in primary tumors and in four patients also in intra-abdominal metastases. The [¹⁸F]EF5-uptake in cancer tissue was low compared to physiological excretory pathways, complicating the interpretation of PET/CT images.

Conclusions

[¹⁸F]EF5-PET/CT is not feasible in ovarian cancer imaging in clinical setting due to physiological intra-abdominal [¹⁸F]EF5-accumulation. However, it may be useful when used complementarily to FDG-PET/CT.

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin. 2017;67(1):7–30 Available from: http://doi.wiley.com/10.3322/caac.21387.CrossRef

Bristow R, Tomacruz R, Armstrong DK, Trimble E, Montz F. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the paltinum era: a meta-analysis. J Clin Oncol. 2002;20:1248–59.CrossRef

Komar G, Lehtiö K, Seppänen M, Eskola O, Levola H, Lindholm P, et al. Prognostic value of tumour blood flow, [18F]EF5 and [18F]FDG PET/CT imaging in patients with head and neck cancer treated with radiochemotherapy. Eur J Nucl Med Mol Imaging. 2014:2042–50.

Kinoshita T, Fujii H, Hayashi Y, Kamiyama I, Ohtsuka T, Asamura H. Lung cancer prognostic significance of hypoxic PET using 18 F-FAZA and 62 Cu-ATSM in non-small-cell lung cancer. 2016;91:56–66.

Qian Y, Eyben R Von, Liu Y, Chin FT, Miao Z, Apte S, et al. F-EF5 PET-based imageable hypoxia predicts local recurrence in tumors treated with highly conformal radiation therapy. Radiat Oncol Biol. 2018;1–10. Available from: https://doi.org/10.1016/j.ijrobp.2018.03.045.

Holmes D. Ovarian cancer: beyond resistance. Nature. 2015;527(7579):S217.CrossRef

Shen W, Li H, Liu L, Cheng J. Expression levels of PTEN, HIF-1 α, and VEGF as prognostic factors in ovarian cancer. Eur Rev Med Pharmacol Sci. 2017;21:2596–603.PubMed

Wilson WR, Hay MP. Hypoxia influences many aspects of the biology of tumours and their responses to therapy. Nat Publ Gr. 2011;11.

Ziemer LS, Evans SM, Kachur A V, Shuman AL, Cardi CA, Jenkins WT, et al. Original article noninvasive imaging of tumor hypoxia in rats using the 2-nitroimidazole 18 F-EF5. 2003;30(2).

10.

Gaertner FC, Souvatzoglou M, Brix G, Beer AJ. Imaging of hypoxia using PET and MRI. Curr Pharm Biotechnol. 2012 [cited 2019 Dec 19];13(4):552–570. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22214501.

11.

Chapman JD, Franko AJ, Sharplin J. A marker for hypoxic cells in tumours with potential clinical applicability. Br J Cancer. 1981;43(4):546–50.CrossRef

12.

Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, et al. Biodistribution and dosimetry of 18F-EF5 in cancer patients with preliminary comparison of 18F-EF5 uptake versus EF5 binding in human glioblastoma. Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2048–59.CrossRef

13.

Rasey JS, Grunbaum Z, Magee S, Nelson NJ, Olive PL, Durand RE, et al. Characterization of radiolabeled fluoromisonidazole as a probe for hypoxic cells. Radiat Res. 1987 Aug;111(2):292.CrossRef

14.

Komar G, Seppänen M, Eskola O, Lindholm P, Grönroos TJ, Forsback S, et al. 18F-EF5: a new PET tracer for imaging hypoxia in head and neck cancer. J Nucl Med. 2008;49(12):1944–51.CrossRef

15.

Vaupel P, Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 2007[cited 2019 Sep 16];26(2):225–39. Available from: http://link.springer.com/10.1007/s10555-007-9055-1.

16.

Rankin EB, Giaccia AJ. Hypoxic control of metastasis. Science. 2016 [cited 2019 Sep 16];352(6282):175–180. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27124451.

17.

Cormio G, Rossi C, Cazzolla A, Resta L, Loverro G, Greco P, et al. Distant metastases in ovarian carcinoma. Int J Gynecol Cancer. [cited 2019 19];13(2):125–129. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12657111.

18.

Natarajan S, Foreman KM, Soriano MI, Rossen NS, Shehade H, Fregoso DR, et al. Collagen remodeling in the hypoxic tumor-mesothelial niche promotes ovarian cancer metastasis. Cancer Res [Internet]. 2019 [cited 2019 Sep 16];79(9):2271–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/30862717.

19.

Busch TM, Hahn SM, Wileyto EP, Koch CJ, Fraker DL, Zhang P, et al. Hypoxia and photofrin uptake in the intraperitoneal carcinomatosis and sarcomatosis of photodynamic therapy patients. Clin Cancer Res. 2004;10(14):4630–8.CrossRef

20.

Silvoniemi A, Suilamo S, Laitinen T, Forsback S. Repeatability of tumour hypoxia imaging using [ 18 F ] EF5 PET/CT in head and neck cancer. Eur J Nucl Med Mol Imaging [Internet]. 2017; Available from: https://doi.org/10.1007/s00259-017-3857-3%0AORIGINALARTICLE%0ARepeatability.

21.

Yapp DTT, Woo J, Kartono A, Sy J, Oliver T, Skov KA, et al. Non-invasive evaluation of tumour hypoxia in the Shionogi tumour model for prostate cancer with 18 F-EF5 and positron emission tomography. BJU Int. 2007 1 [cited 2019 Sep 19];99(5):1154–60. Available from: http://doi.wiley.com/10.1111/j.1464-410X.2007.06761.x.

22.

Warburg O. Über den Stoffwechsel der Carcinomzelle. Naturwissenschaften. 1924;12(50):1131–7.CrossRef

23.

Eskola O, Grönroos TJ, Forsback S, Tuomela J, Komar G, Bergman J, et al. Tracer level electrophilic synthesis and pharmacokinetics of the hypoxia tracer [ 18F]EF5. Mol Imaging Biol. 2012;14(2):205–12.CrossRef

24.

Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, et al. Radiation dosimetry and biodistribution of the hypoxia tracer ¹⁸ F-EF5 in oncologic patients. Cancer Biother Radiopharm. 2012;27(7):412–9 Available from: http://online.liebertpub.com/doi/abs/10.1089/cbr.2011.1130.CrossRef

Title: The feasibility of [18F]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study
Authors: Maren Laasik
Johanna Hynninen
Sarita Forsback
Tommi Noponen
Marko Seppänen
Sakari Hietanen
Publication date: 01-12-2020
Publisher: Springer Berlin Heidelberg
Keywords: Metastasis
Ovarian Cancer
Ovarian Cancer
Published in: EJNMMI Research / Issue 1/2020
Electronic ISSN: 2191-219X
DOI: https://doi.org/10.1186/s13550-020-00689-z

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The feasibility of [¹⁸F]EF5-PET/CT to image hypoxia in ovarian tumors: a clinical study

Abstract

Rationale

Methods

Results

Conclusions

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Rationale

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Brown adipose tissue uptake of triglyceride-rich lipoprotein-derived fatty acids in diabetic or obese mice under different temperature conditions

Differences in [18F]FDG uptake in BAT of UCP1 −/− and UCP1 +/+ during adrenergic stimulation of non-shivering thermogenesis

A DROP-IN beta probe for robot-assisted 68Ga-PSMA radioguided surgery: first ex vivo technology evaluation using prostate cancer specimens

Interobserver agreement of [68Ga]Ga-PSMA-11 PET/CT images interpretation in men with newly diagnosed prostate cancer

Myocardial perfusion reserve of kidney transplant patients is well preserved

Preliminary evidence of imaging of chemokine receptor-4-targeted PET/CT with [68Ga]pentixafor in non-Hodgkin lymphoma: comparison to [18F]FDG